Bernd Traupe

Title: Bernd Traupe: Innovator in Human Cytomegalovirus Research

Introduction

Bernd Traupe is a notable inventor based in Hausen, Germany. He has made significant contributions to the field of virology, particularly in the study of human cytomegalovirus (HCMV). With a total of 2 patents, his work has implications for vaccine development and diagnostic reagents.

Latest Patents

Traupe's latest patents include the structural phosphoprotein (PP150) of human cytomegalovirus. This phosphorylated structural protein, with a molecular weight of about 150 kd, is highly immunogenic and is reliably recognized by human antisera. The protein can be prepared, in whole or in immunogenic sections, through gene manipulation after the assignment and sequencing of the gene. Such proteins are suitable as reagents, for example, in an ELISA, and as constituents of vaccines. Another patent focuses on the peptide of the structural phosphoprotein (PP150) of HCMV, emphasizing its immunogenic properties and potential applications in vaccine development.

Career Highlights

Throughout his career, Bernd Traupe has worked with prominent companies in the diagnostics field, including Behring Diagnostics GmbH. His expertise in virology and protein manipulation has positioned him as a key figure in the development of innovative diagnostic tools and vaccines.

Collaborations

Traupe has collaborated with notable colleagues such as Gerhard Jahn and Birgit-Christine Scholl. These partnerships have furthered research and development in the field of human cytomegalovirus.

Conclusion

Bernd Traupe's contributions to the field of virology, particularly through his patents related to human cytomegalovirus, highlight his role as an innovator in medical research. His work continues to influence the development of diagnostic and therapeutic solutions.